Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: A case-control study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Tinholt, Mari ^a,b,c   Viken, Marte Kathrine ^a   Dahm, Anders Erik ^b   Moen Vollan, Hans Kristian ^a,d,e   Sahlberg, Kristine Kleivi ^a,d,f   Garred, Øystein ^a   Børresen Dale, Anne Lise ^a,d   Jacobsen, Anne Flem ^a,c   Kristensen, Vessela ^a,d,g   Bukholm, Ida ^g   Kåresen, Rolf ^a,c   Schlichting, Ellen ^a   Skretting, Grethe ^a,b   Lie, Benedicte Alexandra ^a   Sandset, Per Morten ^a,b,c   Iversen, Nina ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f Akershus University Hospital ^*  (Norway)

^g AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Activated protein C resistance; Breast cancer; D dimer; Factor V Leiden; Genotype phenotype correlations; Hormone receptor status; Prothrombin G20210A; Single nucleotide polymorphisms; Tissue factor pathway; Triple negative status

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; D DIMER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN C; PROTEIN S; THROMBOPLASTIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; PROCR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BREAST CANCER; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; EPCR GENE; F10 GENE; F5 GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RESISTANCE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; BLOOD; BREAST TUMOR; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HEMOSTASIS; METABOLISM; MIDDLE AGED; ODDS RATIO; PATHOLOGY; RISK; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIGENS, CD; BLOOD COAGULATION; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FACTOR V; FACTOR X; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEMOSTASIS; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; RISK; SIGNAL TRANSDUCTION; THROMBOPLASTIN;

EID: 84964312469     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-845     Document Type: Article

References (47)

1. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA: Activated-protein-C resistance in cancer patients. Haemostasis 1997, 27:112-118.
2. Nijziel MR, van Oerle R, Christella M, Thomassen LG, van Pampus EC, Hamulyak K, Tans G, Rosing J: Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 2003, 120:117-122.
3. Paspatis GA, Sfyridaki A, Papanikolaou N, Triantafyllou K, Livadiotaki A, Kapsoritakis A, Lydataki N: Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb 2002, 32:2-7.
4. Franchini M, Montagnana M, Favaloro EJ, Lippi G: The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. Semin Thromb Hemost 2009, 35:644-653.
5. Kohli M, Fink LM, Spencer HJ, Zent CS: Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 2002, 13:1-5.
6. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prove A, Lemmens J, Vermeulen P: Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002, 86:389-395.
7. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, Zielinski C, Pabinger I: High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012, 97:1158-1164.
8. Lindahl AK, Sandset PM, Abildgaard U, Andersson TR, Harbitz TB: High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 1989, 155:389-393.
9. Iversen N, Lindahl AK, Abildgaard U: Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998, 102:889-895.
10. De Lucia D, De Vita F, Orditura M, Renis V, Belli A, Conte M, di Grazia M, Iacoviello L, Donati MB, Catalano G: Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori 1997, 83:948-952.
11. Sarig G, Michaeli Y, Lanir N, Brenner B, Haim N: Mechanisms for acquired activated protein C resistance in cancer patients. J Thromb Haemost 2005, 3:589-590.
12. Boccaccio C, Comoglio PM: Genetic link between cancer and thrombosis. J Clin Oncol 2009, 27:4827-4833.
13. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH: The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012, 119:924-932.
14. Schaffner F, Ruf W: Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008, 34:147-153.
15. Disse J, Petersen HH, Larsen KS, Persson E, Esmon N, Esmon CT, Teyton L, Petersen LC, Ruf W: The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem 2011, 286:5756-5767.
16. Schaffner F, Yokota N, Carneiro-Lobo T, Kitano M, Schaffer M, Anderson GM, Mueller BM, Esmon CT, Ruf W: Endothelial protein C receptor function in murine and human breast cancer development. PLoS One 2013, 8:e61071.
17. Mozsik G, Rumi G, Domotor A, Figler M, Gasztonyi B, Papp E, Par A, Par G, Belagyi J, Matus Z, Melegh B: Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary. World J Gastroenterol 2005, 11:7646-7650.
18. Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H: Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol 2011, 29:1722-1727.
19. Battistelli S, Stefanoni M, Genovese A, Vittoria A, Cappelli R, Roviello F: Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer. World J Gastroenterol 2006, 12:4179-4180.
20. Pihusch R, Danzl G, Scholz M, Harich D, Pihusch M, Lohse P, Hiller E: Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002, 94:3120-3126.
21. Tormene D, Beltramello P, Perlati M, Brandolin B, Barbar S, De Toffoli G, Simioni P: The risk of cancer progression in women with gynecological malignancies and thrombophilic polymorphisms: a pilot case-control study. Clin Appl Thromb Hemost 2009, 15:535-539.
22. Vairaktaris E, Yapijakis C, Wiltfang J, Ries J, Vylliotis A, Derka S, Vasiliou S, Neukam FW: Are factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res 2005, 25:2561-2565.
23. Eroglu A, Ozturk A, Akar N: Association between the-402GA,-401GT, and-323ins10-bp polymorphisms of factor VII gene and breast cancer. Breast Cancer 2011, 18:282-285.
24. Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR: Molecular classification of breast cancer. Virchows Arch 2014, 465:1-14.
25. Bergrem A, Dahm AE, Jacobsen AF, Mowinckel MC, Sandvik L, Sandset PM: Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism. Br J Haematol 2011, 154:241-247.
26. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003, 33:4-15.
27. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D: Efficiency and power in genetic association studies. Nat Genet 2005, 37:1217-1223.
28. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol 1995, 57:289-300.
29. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI: SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008, 24:2938-2939.
30. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, Weng S, Cherry JM, Snyder M: Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012, 22:1790-1797.
31. Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, Maouche S, Germain M, Lackner K, Rossmann H, Eleftheriadis M, Sinning CR, Schnabel RB, Lubos E, Mennerich D, Rust W, Perret C, Proust C, Nicaud V, Loscalzo J, Hubner N, Tregouet D, Munzel T, Ziegler A, Tiret L, Blankenberg S, Cambien F: Genetics and beyond-the transcriptome of human monocytes and disease susceptibility. PLoS One 2010, 5:e10693.
32. Zakai NA, Lange L, Longstreth WT Jr, O'Meara ES, Kelley JL, Fornage M, Nikerson D, Cushman M, Reiner AP: Association of coagulation-related and inflammation-related genes and factor VIIc levels with stroke: the Cardiovascular Health Study. J Thromb Haemost 2011, 9:267-274.
33. Vylliotis A, Yapijakis C, Nkenke E, Nisyrios T, Avgoustidis D, Adamopoulou M, Ragos V, Vassiliou S, Koronellos N, Vairaktaris E: Effect of thrombosis-related gene polymorphisms upon oral cancer: a regression analysis. Anticancer Res 2013, 33:4033-4039.
34. Tripodi A, Legnani C, Palareti G, Chantarangkul V, Mannucci PM: More on: high thrombin generation and the risk of recurrent venous thromboembolism. J Thromb Haemost 2009, 7:906-907.
35. Stepien E, Plicner D, Branicka A, Stankiewicz E, Pazdan A, Sniezek-Maciejewska M, Gorkiewicz I, Kapelak B, Sadowski J: Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease. Pol Arch Med Wewn 2007, 117:297-305.
36. Tas F, Kilic L, Duranyildiz D: Coagulation tests show significant differences in patients with breast cancer. Tumour Biol 2014, 35:5985-5992.
37. Negaard HF, Iversen PO, Ostenstad B, Mowinckel MC, Sandset PM: Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 2008, 6:1482-1487.
38. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G: Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002, 13:187-192.
39. Williamson D, Brown K, Luddington R, Baglin C, Baglin T: Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood 1998, 91:1140-1144.
40. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C: Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000, 18:600-608.
41. Oya M, Akiyama Y, Okuyama T, Ishikawa H: High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001, 31:388-394.
42. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S: Evaluating prethrombotic state in lung cancer using molecular markers. Chest 1993, 103:196-200.
43. Tas F, Ciftci R, Kilic L, Serilmez M, Karabulut S, Duranyildiz D: Clinical and prognostic significance of coagulation assays in gastric cancer. J Gastrointest Cancer 2013, 44:285-292.
44. Knowlson L, Bacchu S, Paneesha S, McManus A, Randall K, Rose P: Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J Clin Pathol 2010, 63:818-822.
45. Yigit E, Gonullu G, Yucel I, Turgut M, Erdem D, Cakar B: Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur J Intern Med 2008, 19:602-607.
46. Chew HK, Wun T, Harvey DJ, Zhou H, White RH: Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007, 25:70-76.
47. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD: Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004, 2:2107-2114.